Study guide
5.2 Sedative, Hypnotic, Anxiolytic & Gabapentinoid Misuse
Certified Addictions Registered Nurse CARN
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Introduction & Exam Overview
1.1 CARN Exam Overview, Eligibility & Requirements 1.2 How to Use This Study Guide & Preparation Strategy
2 Chapter 2: Assessment & Screening
2.1 DSM-5-TR Substance Use Disorder Diagnostic Criteria & Severity Classification 2.2 Standardized Screening Tools: AUDIT, DAST-10, CAGE, CRAFFT & ASSIST 2.3 Withdrawal Severity Rating Scales: CIWA-Ar & COWS 2.4 Neonatal & Special Population Assessment: Finnegan, Eat-Sleep-Console & Life Stages 2.5 Assessment of Co-Occurring Psychiatric & Medical Disorders
3 Chapter 3: Planning & Intervention
3.1 ASAM Criteria & Continuum of Placement Care 3.2 Motivational Interviewing (OARS) & Transtheoretical Stages of Change 3.3 Trauma-Informed Care Principles & Addictions Nursing Practice 3.4 Family Dynamics, Codependency, CRAFT Model & Family Support Systems 3.5 Nursing Diagnosis, Outcome Identification & Individualized Addictions Care Planning
4 Chapter 4: Clinical Management & Pharmacotherapy
4.1 Alcohol Withdrawal Syndrome Management & Complication Prevention 4.2 Opioid Withdrawal Management & Symptom-Triggered Protocols 4.3 Medications for Opioid Use Disorder (MOUD: Methadone, Buprenorphine & Extended-Release Naltrexone) 4.4 Pharmacotherapy for Alcohol & Nicotine Use Disorders 4.5 Harm Reduction Strategies: Naloxone, Fentanyl Test Strips & Syringe Services 4.6 Pain Management in Patients with Substance Use Disorders
5 Chapter 5: Substance-Specific Disorders, Prevention & Patient Education
5.1 Stimulant Use Disorders: Cocaine, Amphetamines & Caffeine 5.2 Sedative, Hypnotic, Anxiolytic & Gabapentinoid Misuse 5.3 Cannabis & Hallucinogen Use Disorders 5.4 Tobacco Use Disorder, Vaping & Cessation Interventions 5.5 Prevention, Brief Intervention, Patient Education & Behavioral Addictions
6 Chapter 6: Evaluation, Recovery & Continuing Care
6.1 Relapse Prevention Models: Marlatt's Model, Urge Surfing & High-Risk Situations 6.2 Mutual-Help Groups & Peer Recovery Support: 12-Step, SMART Recovery & Peer Specialists 6.3 Recovery Capital, Social Determinants of Health & Holistic Wellness 6.4 Transitions of Care, Discharge Planning & Long-Term Recovery Management
7 Chapter 7: Professional Role, Ethics & Legal Issues
7.1 ANA/IntNSA Scope & Standards of Addictions Nursing Practice 7.2 Confidentiality Laws: 42 CFR Part 2 vs. HIPAA & 2024 Alignment Updates 7.3 Legal & Ethical Issues, Stigma Reduction & Person-First Language
5.2 Sedative, Hypnotic, Anxiolytic & Gabapentinoid Misuse
Key Takeaways Explain This Topic AI
Medication misuse — sedatives, hypnotics, anxiolytics, and gabapentinoids — carries a 10% weight (15-17 items) on the official CARN blueprint and most often involves benzodiazepines, Z-drugs, barbiturates, gabapentin, or pregabalin.
Benzodiazepine withdrawal is cross-tolerant with alcohol withdrawal and equally life-threatening (seizures, delirium); onset is 24-72 hours for short-acting agents and 2-7 days for long-acting agents.
Flumazenil is contraindicated in chronic benzodiazepine users or mixed overdoses because antagonism precipitates refractory withdrawal seizures; it is reserved for iatrogenic reversal in benzodiazepine-naive patients.
Safe discontinuation requires conversion to a long-acting agent followed by a gradual taper of roughly 10-25% every 1-2 weeks — never abrupt cessation after prolonged use.
Gabapentinoids (gabapentin, pregabalin) are increasingly misused with opioids to potentiate euphoria and cause additive respiratory depression; abrupt cessation produces an alcohol-like withdrawal syndrome requiring a taper.
Last updated: August 2026
5.2 Sedative, Hypnotic, Anxiolytic & Gabapentinoid Misuse
The official CARN blueprint dedicates 10% of the exam (approximately 15-17 items) to medication misuse involving sedatives, hypnotics, anxiolytics, and gabapentinoids. Because these agents are legally prescribed, the CARN nurse must distinguish therapeutic use from misuse, recognize dangerous co-use with opioids, and manage a withdrawal syndrome that — like alcohol withdrawal — can kill.
Agents and Pharmacology
Class Representative Agents Mechanism Key Risk
Benzodiazepines Alprazolam, lorazepam, diazepam, clonazepam GABA-A positive allosteric modulators (increase chloride channel opening frequency ) Dependence, falls, respiratory depression with opioids
Barbiturates Phenobarbital GABA-A modulators that prolong chloride channel opening; narrow therapeutic index Severe overdose toxicity; lethal in overdose
Z-drugs Zolpidem, eszopiclone, zaleplon Selective BZ1 (omega-1) receptor agonists Complex sleep behaviors (sleep-driving), dependence
Gabapentinoids Gabapentin, pregabalin (Schedule V) Alpha-2-delta voltage-gated calcium channel ligands Misuse with opioids; additive respiratory depression
Misuse Patterns and Screening
Misuse frequently involves combining benzodiazepines or gabapentinoids with opioids to potentiate euphoria — a practice that multiplies respiratory depression and overdose death risk (the FDA requires boxed warnings on co-prescribing). Nursing assessment includes Prescription Drug Monitoring Program (PDMP) review, pill counts, non-punitive urine drug testing, and screening for 'doctor shopping.' In older adults , the American Geriatrics Society Beers Criteria flag benzodiazepines and Z-drugs for avoidance because of falls, delirium, and cognitive impairment.
Recognizing Prescribed-Medication Misuse
Risk factors and red flags for sedative misuse include a personal or family history of substance use disorder, long-term high-dose prescriptions, co-prescribed opioids, escalating doses without prescriber approval, early refill requests, reports of 'lost' medication, and prescriptions from multiple providers. Nursing responses stay non-punitive and structured: verify the PDMP, use pill counts and non-judgmental urine drug testing, educate on safe storage, and advocate for taper plans rather than abrupt discontinuation.
Overdose Management
Isolated benzodiazepine overdose is rarely fatal and is managed supportively (airway protection, ventilation). Danger escalates sharply with opioid, alcohol, or barbiturate co-ingestion.
High-yield safety rule: Flumazenil , a competitive benzodiazepine antagonist, is contraindicated in chronic benzodiazepine users, unknown or mixed ingestions, and patients with seizure history — abrupt antagonism precipitates refractory withdrawal seizures. Its only accepted role is reversing iatrogenic procedural sedation in benzodiazepine-naive patients. When opioid co-ingestion is possible, administer naloxone first and support ventilation.
Barbiturate overdose deserves separate mention: with no reversal agent and a narrow therapeutic index, barbiturate poisoning causes profound, prolonged respiratory depression managed with aggressive supportive ventilation. Paradoxically, phenobarbital's long half-life and predictable kinetics make it useful in some medically managed sedative-withdrawal loading protocols.
Sedative Withdrawal: Life-Threatening Like Alcohol
Benzodiazepines are cross-tolerant with alcohol at the GABA-A receptor, and sedative withdrawal reproduces the alcohol withdrawal spectrum: tremor, diaphoresis, tachycardia, hypertension, perceptual disturbances, generalized seizures , and delirium .
Withdrawal Onset by Half-Life
Short-acting agents (alprazolam, lorazepam, oxazepam, zolpidem): onset 24-72 hours after cessation.
Long-acting agents (diazepam, clonazepam): onset 2-7 days after cessation.
Distinguish rebound (short-lived return of the original anxiety or insomnia, lasting 1-3 days) from true withdrawal (new symptoms such as tremor, perceptual distortion, and autonomic instability). Unlike alcohol withdrawal, there is no universally adopted bedside severity scale (the CIWA-B exists as a research tool); nurses monitor vital signs, tremor, mental status, and seizure precautions.
Evidence-Based Taper Protocols
Never stop abruptly after prolonged regular use — seizure risk is real even without a prior seizure history.
Convert to a long-acting agent (e.g., diazepam or clonazepam) for smooth receptor coverage.
Reduce the dose by approximately 10-25% every 1-2 weeks , slowing the pace in the final quarter of the taper; individualize to symptoms.
Severe, high-dose, or polysubstance dependence warrants medically monitored inpatient tapering (ASAM Level 3.7) ; some protocols use phenobarbital loading.
Treat the underlying condition non-pharmacologically: CBT for anxiety, CBT-I for insomnia.
Gabapentinoid Misuse and Withdrawal
Gabapentin and pregabalin misuse has risen sharply, particularly among people with opioid use disorder (to potentiate opioid effects) and in correctional settings; pregabalin is federally Schedule V. Combined with opioids, gabapentinoids produce additive respiratory depression . Abrupt cessation after chronic high-dose use produces a withdrawal syndrome resembling alcohol/sedative withdrawal — anxiety, insomnia, nausea, diaphoresis, tachycardia — managed by gradual taper over weeks rather than abrupt discontinuation.
Nursing Care Summary
Verify all sedative prescriptions against the PDMP; use non-stigmatizing language when discussing misuse.
Institute seizure precautions (padded rails, suction and airway equipment) during sedative withdrawal.
Educate every patient receiving opioids plus sedatives or gabapentinoids about overdose risk and provide naloxone.
Advocate for taper plans and non-pharmacological anxiety/insomnia treatments rather than indefinite continuation.